TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31325145

Group type: EXPERIMENTAL
Intervention: Perifosine (PRF) 600 mg loading dose (4 divided doses on day 1) followed by 100 mg daily until disease progression or intolerable toxicity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Perifosine (PRF) for patients with anaplastic astrocytoma
Number of subjects: 30
Study: 29518077

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Short term psychodynamic therapy (PDT)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) and Short term psychodynamic therapy (PDT)
Number of subjects: 495
Study: 26539836

Group type: EXPERIMENTAL
Intervention: Lidopat(®) 5% skin patch
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo vehicle patch
Number of subjects: 44
Study: 24718702

Group type: EXPERIMENTAL
Intervention: Concentrated ambient ultrafine particles (UCAPS) for 2 hours
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clean air for 2 hours
Number of subjects: 34
Study: 23110506

Group type: EXPERIMENTAL
Intervention: 20 hair grafts in the experimental square
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nongrafted control square
Number of subjects: 10
Study: 20951286

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Novel Endodontic Cement (NEC)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both MTA and NEC
Number of subjects: 32
Study: 17376044

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menatetrenone) at 45 mg per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no vitamin K2)
Number of subjects: 60
Study: 16327351

Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Donepezil
Number of subjects: 63
Study: 12046996

Group type: EXPERIMENTAL
Intervention: Patient-held record (PHR)
Number of subjects: 244

Group type: COMPARATOR
Intervention: No PHR
Number of subjects: 244
Study: 10209372

Group type: EXPERIMENTAL
Intervention: Propofol/propofol auto-co-induction
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Midazolam/propofol co-induction
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 54
Study: 7789025

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Deep venous thrombosis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: No deep venous thrombosis
Number of subjects: 72
Study: 1954810

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg three times daily for 24 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 94
Study: 7144066

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31972958

Group type: EXPERIMENTAL
Intervention: Sil‐Oss® (experimental material)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Bio‐Oss® (control material)
Number of subjects: 33
Study: 30860552

Group type: EXPERIMENTAL
Intervention: High-dose prenatal vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose prenatal vitamin D supplementation
Number of subjects: 0
Study: 28636505

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Aerobic Continuous Training (ACT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both AIT and ACT
Number of subjects: 200
Study: 27107153

Group type: EXPERIMENTAL
Intervention: Ovarian function suppression plus standard tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors as an alternative to tamoxifen with ovarian suppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard tamoxifen
Number of subjects: 0
Study: 24521787

Group type: EXPERIMENTAL
Intervention: Heated humidified high-flow nasal cannula (HHHFNC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Inhaled hypertonic saline solution (HSS)
Number of subjects: 75
Study: 22284962

Group type: EXPERIMENTAL
Intervention: Lack of periconceptional vitamins or supplements that contain folic acid
Number of subjects: 14721

Group type: COMPARATOR
Intervention: Periconceptional vitamins or supplements that contain folic acid
Number of subjects: 14721
Study: 20408346

Group type: EXPERIMENTAL
Intervention: Lactobacillus sakei KCTC 10755BP
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 17588826

Group type: EXPERIMENTAL
Intervention: Lovastatin 20-40 mg/day
Number of subjects: 6605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6605
Study: 16386098

Group type: EXPERIMENTAL
Intervention: Palm glucose testing
Number of subjects: 181

Group type: COMPARATOR
Intervention: Fingertip glucose testing
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Healthcare professional conducted testing
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Error grid analysis
Number of subjects: 181
Study: 12422101

Group type: EXPERIMENTAL
Intervention: External pneumatic compression (EPC) devices
Number of subjects: 44

Group type: COMPARATOR
Intervention: Unfractionated heparin injections
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both EPC devices and unfractionated heparin injections
Number of subjects: 44
Study: 9854453

Group type: EXPERIMENTAL
Intervention: beta-blockers (metoprolol or propranolol)
Number of subjects: 42

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 42
Study: 7832192

Group type: EXPERIMENTAL
Intervention: rhGM-CSF (recombinant human granulocyte‐macrophage colony‐stimulating factor)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: rhGM-CSF with prophylactic treatment with vitamin K
Number of subjects: 18
Study: 2170883

Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha 2‐adrenergic antagonist)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clonidine (alpha 2‐adrenergic agonist)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (control for yohimbine)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Asymptomatic comparison group
Number of subjects: 9
Study: 326219

Group type: EXPERIMENTAL
Intervention: Paracetamol + Caffeine (Finimal)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 216

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 216
Study: 31813388

Group type: EXPERIMENTAL
Intervention: Drink containing 700 mg of Ca (DAIR)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet containing 1200 mg Ca/d
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Educational activities
Number of subjects: 14

Group type: COMPARATOR
Intervention: Drink containing 0 mg of Ca (CONT)
Number of subjects: 14
Study: 30537063

Group type: EXPERIMENTAL
Intervention: Topical cysteamine cream applied once daily for 2 and 4 months.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Topical cysteamine cream applied biweekly after initial treatment.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Topical cysteamine cream.
Number of subjects: 1
Study: 26895847

Group type: EXPERIMENTAL
Intervention: SUPPORT (access to online social support tools)
Number of subjects: 63

Group type: COMPARATOR
Intervention: NO SUPPORT (no access to online social support tools)
Number of subjects: 63
Study: 26116930

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine (LDX) 70 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (PBO) 0 mg
Number of subjects: 43
Study: 23261491

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) consisting of two sessions
Number of subjects: 515

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 515
Study: 21830062

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Initial CPAP treatment in OSAS group
Number of subjects: 52

Group type: COMPARATOR
Intervention: CompSAS patients
Number of subjects: 52
Study: 19240454

Group type: EXPERIMENTAL
Intervention: Residents' self-review of charts
Number of subjects: 74
Study: 17489880

Group type: EXPERIMENTAL
Intervention: NPD + L-phenylalanine (7.5 g/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-protein diet (HPD, 141.3 +/‐ 3.7 g/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal-protein diet (NPD, 73.2 +/‐ 2.6 g/day)
Number of subjects: 6
Study: 15378679

Group type: EXPERIMENTAL
Intervention: L-theanine (200 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11413085

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 439

Group type: COMPARATOR
Intervention: Co-amilozide (hydrochlorothiazide 25 mg and amiloride 2.5 mg)
Number of subjects: 439
Study: 9626118

Group type: EXPERIMENTAL
Intervention: Diazoxide (DZ) 2 mg/kg BW.day; maximum 200 mg/day, divided into 3 doses for 8 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7701041

Group type: COMPARATOR
Intervention: Nicotine (0, 2, 4, 8, and 12 micrograms/kg) administered by measured‐dose nasal spray
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nicotine (12 micrograms/kg) administered by measured‐dose nasal spray
Number of subjects: 18
Study: 3665756

Group type: EXPERIMENTAL
Intervention: Rate-adapted pacing (Activitrax system)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fixed-rate pacing
Number of subjects: 23
Study: 30222788

Group type: EXPERIMENTAL
Intervention: Combined intravenous (IV) and intra-articular (IA) administration of tranexamic acid (TXA)
Number of subjects: 154

Group type: COMPARATOR
Intervention: IV only administration of tranexamic acid (TXA)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combined IV and IA administration of TXA
Number of subjects: 154

Group type: COMPARATOR
Intervention: IV only administration of TXA
Number of subjects: 154
Study: 27400145

Group type: EXPERIMENTAL
Intervention: Combined Spinal Epidural Anesthesia (CSEA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both CSEA and GA
Number of subjects: 22
Study: 23436914

Group type: EXPERIMENTAL
Intervention: Atorvastatin for 36 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22512878

Group type: COMPARATOR
Intervention: Control group (normal amino acid solution in the same quantity for 7 days)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous glutamine
Number of subjects: 45
Study: 20227716

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg zinc + 60 mg iron + 250 microg folic acid)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo (60 mg iron + 250 microg folic acid)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study: 18853559

Group type: EXPERIMENTAL
Intervention: Higher visualisation scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower visualisation scores
Number of subjects: 0
Study: 15795200

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needling followed by high-energy shock-wave therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Shock-wave therapy alone
Number of subjects: 40
Study: 12493263

Group type: EXPERIMENTAL
Intervention: Fosmidomycin for 5 days (1.2 g every 8 h)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fosmidomycin for 4 days (1.2 g every 8 h)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fosmidomycin for 3 days (1.2 g every 8 h)
Number of subjects: 27
Study: 10909495

Group type: EXPERIMENTAL
Intervention: Program I (individual, motivating instructions of oral cavity hygiene, 10 meetings)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Program II (expanded educational activity among children and parents)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Program III (expanded educational activity, professional mechanical tooth-cleaning, fissure sealants, intensive dental care, proximal surface cleaning)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control group K (no specific intervention)
Number of subjects: 223
Study: 7864422

Group type: EXPERIMENTAL
Intervention: Enflurane at 0.3% end-tidal level (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enflurane at 0.6% end-tidal level (Group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enflurane at 1.2% end-tidal level (Group III)
Number of subjects: 30
Study: 2387655

Group type: EXPERIMENTAL
Intervention: SMS 201-995 (10-hour i.v. infusion at a rate of 8 g/min)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 7016245

Group type: EXPERIMENTAL
Intervention: Graded pressure stockings
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no stockings)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Blood transfusion during operation
Number of subjects: 76
Study: 30900268

Group type: EXPERIMENTAL
Intervention: Energy-enriched formula (EE-formula) (1 kcal/mL)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normocaloric formula (0.67 kcal/mL)
Number of subjects: 59
Study: 31084562

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) applied three times a week for 4 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT) applied once a week for 4 weeks
Number of subjects: 43
Study: 27813150

Group type: EXPERIMENTAL
Intervention: Cariex® spray combined with non-surgical periodontal therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cariex® spray alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-surgical periodontal therapy alone
Number of subjects: 24
Study: 25530011

Group type: EXPERIMENTAL
Intervention: Boysenberry beverage (750 mg polyphenols)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Apple fiber beverage (7.5 g dietary fiber)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Boysenberry plus apple fiber beverage (750 mg polyphenols plus 7.5 g dietary fiber)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Boysenberry juice beverage
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Apple fiber beverage
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Boysenberry juice plus apple fiber beverage
Number of subjects: 25
Study: 25146288

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 954

Group type: COMPARATOR
Intervention: No vaccine (Control)
Number of subjects: 954
Study: 22520095

Group type: EXPERIMENTAL
Intervention: CTC group (CT cisternography considered before treatment)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Surgical group (surgery without considering CTC results)
Number of subjects: 52
Study: 19201654

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 897

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 897
Study: 16762429

Group type: EXPERIMENTAL
Intervention: Priming effect in mild-AD
Number of subjects: 22

Group type: COMPARATOR
Intervention: Object identification task performance
Number of subjects: 22

Group type: COMPARATOR
Intervention: Recall task performance
Number of subjects: 22
Study: 15319041

Group type: EXPERIMENTAL
Intervention: Standard care plus video conferencing/Internet access
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Standard care plus physiological monitoring
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard home health care (HHC)
Number of subjects: 53
Study: 14727868

Group type: EXPERIMENTAL
Intervention: Liposomal tretinoin (TRE) and benzoyl peroxide (BP) gels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 9612233

Group type: EXPERIMENTAL
Intervention: GHRP-2 (1 microgram/kg body wt)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 8070509

Group type: EXPERIMENTAL
Intervention: Oral lomefloxacin 200 mg with furosemide 40 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral lomefloxacin 200 mg alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Furosemide 40 mg alone
Number of subjects: 8
Study: 3123119

Group type: EXPERIMENTAL
Intervention: Complete intravenous nutritional support (IVF) with all D‐glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete intravenous nutritional support (IVF) with 50% D‐glucose/50% lipid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete intravenous nutritional support (IVF) with D‐glucose/amino acid regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete intravenous nutritional support (IVF) with D‐glucose/lipid/amino acid regimen
Number of subjects: 0
Study: 30356378

Group type: EXPERIMENTAL
Intervention: GHRH plus arginine test in HD group (9 patients with cardiovascular disease)
Number of subjects: 31

Group type: COMPARATOR
Intervention: GHRH plus arginine test in non-HD group (12 patients without cardiovascular disease)
Number of subjects: 31
Study: 27039058

Group type: EXPERIMENTAL
Intervention: Telephone Counseling (TC)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 168
Study: 24196555

Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal repair (TEP) under general anesthesia
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lichtenstein repair under local anesthesia
Number of subjects: 72
Study: 21986868

Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 602

Group type: COMPARATOR
Intervention: non-ART
Number of subjects: 602
Study: 20406831

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (NT) including epirubicin/cyclophosphamide followed by docetaxel alone, docetaxel with capecitabine, or docetaxel followed by capecitabine, with additional trastuzumab treatment for HER2-positive tumors.
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (NT) with trastuzumab for HER2-positive tumors.
Number of subjects: 213

Group type: COMPARATOR
Intervention: Neoadjuvant therapy (NT) with no specific control mentioned.
Number of subjects: 213
Study: 18242480

Group type: EXPERIMENTAL
Intervention: Combined therapy with carvedilol and amiodarone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Carvedilol alone
Number of subjects: 30
Study: 15168002

Group type: EXPERIMENTAL
Intervention: Transurethral Foley catheter removed postoperatively the next morning (Group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Transurethral indwelling catheter left in place until the fifth postoperative day (Group B)
Number of subjects: 86
Study: 11411960

Group type: EXPERIMENTAL
Intervention: Serum NO concentrations measured indirectly in terms of nitrate using colorimetric assay
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Disease activity parameters including C-reactive protein, number of swollen and tender joints, Ritchie articular index, and disease activity scores
Number of subjects: 27
Study: 9839852

Group type: EXPERIMENTAL
Intervention: Chlorhexidine chip in conjunction with scaling and root planing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 0
Study: 8043521

Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 2903425

Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.01 to 0.09 mg single oral doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CV 205‐502 (0.06 mg single oral dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30884661

Group type: EXPERIMENTAL
Intervention: Fermented milk with probiotic (Lactobacillus rhamnosus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fermented milk without probiotic (placebo)
Number of subjects: 0
Study: 28699551

Group type: EXPERIMENTAL
Intervention: Camino Verde intervention
Number of subjects: 0
Study: 26573323

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Treatment (MET)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: MET plus an add-on with eight sessions based on the Community Reinforcement Approach (CRA)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (MET only)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Total abstinence (secondary outcome)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Quality of life (secondary outcome)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Compliance with treatment (secondary outcome)
Number of subjects: 1000
Study: 22733239

Group type: EXPERIMENTAL
Intervention: Mirtazapine with CYP2D6 genotype 0
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mirtazapine with CYP2D6 genotype 0 plus 1
Number of subjects: 68
Study: 21199958

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19638080

Group type: COMPARATOR
Intervention: Medication group (nadolol plus isosorbide‐5‐mononitrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined group (banding ligation plus medications)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 16857509

Group type: EXPERIMENTAL
Intervention: Multiquadrant cortical cleaving hydrodissection and hydrodelineation (n = 48 eyes)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No multiquadrant cortical cleaving hydrodissection, only hydrodelineation (n = 38 eyes)
Number of subjects: 86
Study: 15108863

Group type: EXPERIMENTAL
Intervention: 2% clindamycin vaginal cream (CVC)
Number of subjects: 404

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: CVC
Number of subjects: 404
Study: 11117277

Group type: EXPERIMENTAL
Intervention: 30 mg/day of lycopene (LYC‐O‐MATO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9494599

Group type: EXPERIMENTAL
Intervention: ABVD chemotherapy followed by mediastinal irradiation at a median dose of 36 Gy (range 30.6‐43.2)
Number of subjects: 32
Study: 8416243

Group type: EXPERIMENTAL
Intervention: THAM (tromethamine)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study: 3092976

Group type: EXPERIMENTAL
Intervention: Computer-assisted management (test practices)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control management (control practices)
Number of subjects: 60